Drug · Monoclonal Antibody

Panitumumab

CI-DRUG-00000454Explore in graph →NCIt C1857 CHEMBL1201827 CIViC Approved

Regulatory

Approvals (10)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory6 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Efficacy supplement 2025-01-16 (see label)	approved	Jan 16, 2025	openfda
US FDA	—	Efficacy supplement 2017-06-29 (see label)	approved	Jun 29, 2017	openfda
US FDA	—	Efficacy supplement 2014-05-23 (see label)	approved	May 23, 2014	openfda
US FDA	—	Efficacy supplement 2014-05-23 (see label)	approved	May 23, 2014	openfda
US

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 17 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	35	23	23	180	10	CA, EU, US	Sep 27, 2006	2000-04
Malignant Pancreatic Neoplasm	Phase3	Phase 3	4	3	1	10	0	—	—	2000-04
Malignant Colon Neoplasm	Phase3	Phase 3	2	1	2	15	0	—	—	2004-12
Malignant Esophageal Neoplasm	Phase3	Phase 3	0	0	1	9	0

Curated evidence

Clinical evidence (127)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–50 of 127 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E10
Irinotecan + Panitumumab

Clinical trials

Trials with this intervention (182)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 182 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06509126	Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE-2)	recruiting	Phase 3	500	National Cancer Institute, NaplesOTHER	1	Jul 19, 2024	clinicaltrials
NCT00891930	Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab	completed

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Epidermal growth factor receptor erbB1 inhibitor
Targets: 1 gene
UNII: 6A901E312A
Aliases: Abenix, ABX-EGF, ABX-EGF, Clone E7.6.3, ABX-EGF Monoclonal Antibody, E7.6.3, Human IgG2K Monoclonal Antibody, L01xc08, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Panitumumab, Vectibix, VECTIBIX

Data updated 20 hours agoSource updated unknown

Identifiers

Codes (9)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FE02	PANITUMUMAB
ATC (WHO)	L01XC08	Antineoplastic agents
DIN (Health Canada)

CDKN2A p16 Expression2
Panitumumab	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	3	accepted	EID696 In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab)… (full text at CIViC) PMID 23746666 · Vermorken et al., 2013 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID753 p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone. PMID 23746666 · Vermorken et al., 2013 · Open in CIViC	civic

EGFR G465R2
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID7083 Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC) PMID 29196463 · Strickler et al., 2018 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	4	accepted	EID1058 An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR K467T2
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID7087 Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC) PMID 29196463 · Strickler et al., 2018 · Open in CIViC	civic
Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1082 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic